The Online Investor
Daily M&A
Contrarian Outlook
Stock Option Ideas
Preferred Stock Newsletter
ChartZero.com
Drugs & Pharmaceuticals M&A image Drugs & Pharmaceuticals M&A » By The Online Investor Staff, updated Thu., Mar. 28, 12:42 PM Recent mergers and acquisitions in the Drugs & Pharmaceuticals M&A category.

Slide #63. Henry Schein, Inc. Medivet

Acquirer: Henry Schein, Inc. (NASDAQ:HSIC)
Acquiree: Medivet
Details: Henry Schein, Inc. (NASDAQ: HSIC), the world's largest provider of health care products and services to office-based dental, animal health and medical practitioners, announced today that it has signed a definitive agreement to acquire an 80% ownership position in privately-held Medivet S.A., a leading distributor of animal health products and services in Poland, with sales in 2012 of approximately $80 million.

Schein (Henry) is a provider of health care products and services primarily to office-based dental and medical practitioners, as well as alternate sites of care. Co. conducts its business through two reportable segments: health care distribution; and technology and other services. The health care distribution reportable segment aggregates Co.'s global dental and medical operating segments. Co.'s global technology and other services group provides software, technology and other services to health care practitioners. Co.'s technology group offerings include practice management software systems for dental and medical practitioners.

Henry Schein SEC Filing Email Alerts Service


Open the HSIC Page at The Online Investor »

Company Name:  Schein (Henry) Inc
Stock buyback:  HSIC buyback
Website:  www.henryschein.com
Sector:  Drugs & Pharmaceuticals
Number of ETFs Holding HSIC:  91
Total Market Value Held by ETFs:  $1.65B
Total Market Capitalization:  $9.37B
% of Market Cap. Held by ETFs:  17.62%
 

Open the HSIC Page at The Online Investor (in a new window) »

March 28, 2024    12:42 PM Eastern
Quotes delayed 20 minutes

Email EnvelopeFree HSIC Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Hold (2.44 out of 4)
3rd percentile
(ranked lower than approx. 97% of all stocks covered)

Analysts' Target Price:
HSIC Stock Forecast

Based on Zacks ABR data;
powered by Xignite

Drugs & Pharmaceuticals M&A - Slide 63 of 100 | www.TheOnlineInvestor.com | Copyright © 1998 - 2024, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.